title: Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients.
abstract: This study was aimed to investigate the prognostic value of neutrophil-to-lymphocyte ratio (NLR) in patients with prostate cancer (PCa). A meta-analysis including 14 publications (15 cohorts) with 16,266 patients was performed to evaluate the association between NLR and overall survival (OS), progression-free survival (PFS)/recurrence-free survival (RFS) in PCa using hazard ratio (HR) and 95% confidence intervals (95% CI). The combining data showed that increased NLR predict poor OS (HR = 1.38, 95%CI: 1.22-1.56) and PFS/RFS (HR = 1.24, 95%CI 1.05-1.46) in PCa. Stratified analysis by PCa type, sample size, ethnicity and NLR cut-off value revealed that NLR showed consistent prognostic value in metastatic castration-resistant prostate cancer (mCRPC) patients and predict poor PFS/RFS in Asians, but not in Caucasians. These statistical data suggested that increased NLR could predict poor prognosis in patients with PCa.
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Xiaobin
authors.initials: X
authors.lastname: Gu
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Xianshu
authors.initials: X
authors.lastname: Gao
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Xiaoying
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Qi
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Mingwei
authors.initials: M
authors.lastname: Ma
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Shangbin
authors.initials: S
authors.lastname: Qin
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Hao
authors.initials: H
authors.lastname: Yu
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Shaoqian
authors.initials: S
authors.lastname: Sun
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Dong
authors.initials: D
authors.lastname: Zhou
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Wen
authors.initials: W
authors.lastname: Wang
mesh_terms: D018572:Disease-Free Survival; D006801:Humans; D018655:Lymphocyte Count; D008214:Lymphocytes; D008297:Male; D009504:Neutrophils; D011471:Prostatic Neoplasms / Q000097:blood* / Q000401:mortality*; D015996:Survival Rate